Arvinas, Inc. (ARVN) Covered Calls

You can sell covered calls on Arvinas, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ARVN (prices last updated Wed 4:16 PM ET):

Arvinas, Inc. (ARVN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
18.61 -0.49 18.00 18.61 1.2M - 1.3
Covered Calls For Arvinas, Inc. (ARVN)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Dec 20 17.5 0.65 17.96 -2.6% -316.3%
Jan 17 17.5 2.25 16.36 7.0% 82.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.